2/5 Finding the right words can seem like an insurmountable challenge.

3/5 🏥 Working in paediatric oncology, I was always struck by how few resources exist to support these conversations within families. So, I wrote my own.

4/5 🏥 I’ve written and illustrated a story about cancer, about chemotherapy, radiation, surgery and immunotherapy. About the long journey to recovery and also the possibility, despite everyone’s very best efforts, of death.

5/5 I hope this resource can be of help to parents and loved ones going through the difficult journey of cancer diagnosis and treatment. You are not alone. ♥️🩺

👫 'UNDERSTANDING CANCER' 👫 ‏ – an illustrated book to help communicate with kids

🏥 When the unthinkable happens, how do we to talk to children about cancer? As family, how do we explain what’s happening without overpromising, while making it clear that it's not their fault? amazon.com/dp/B0GNRXG7R9

Excited to share our new paper: ‘Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation’ led by Callum Nattress in collab. with Jonathan Fisher lab (1/13)
aacrjournals.org/cancerres/ar...

Medicine Nobel goes to three researchers who identified immune system’s security guards Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi discovered regulatory T cells that prevent autoimmune disease

This year’s #NobelPrize in Physiology or Medicine has been awarded to three scientists for discovering how the immune system distinguishes friend from foe. https://scim.ag/3Wt5rdi

🏆Announcing our Development Fund 2025 Awardees 🏆 This pump-priming fund enables researchers to explore and launch innovative new ideas. Swipe to see our first four successful applicants and read about all the projects and co-applicants on our website: www.colcc.ac.uk/development-...

Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for antigen-dim cell targeting & avoidance of antigen-dim tumor relapse
@natcomms.nature.com
www.nature.com/articles/s41...

👩‍🔬 Check out the stunning AI-analysed videos of aB7H3 CAR-T killing clumps of patient-derived neuroblastoma generated by our colleagues Prinses Maxima

🔬 CD4 CAR (blue), CD8 CAR (green), live tumours (yellow), dead tumours (red)
Full story nature.com/articles/s41...
@natureportfolio.nature.com

3of3

🔬 Consequently, only high avidity CAR-T both killed targets and proliferated, enabling long-term responses

2of3

🔬 High avidity was required to engage IL-2 production and proliferation, but not necessarily cytotoxicity

1of3

In brief,
🔬 Synaptic avidity was determined by a triad of CAR expression level, scFv-Ag affinity and Ag density

Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function - Nature Communications CAR-T cells have been found to be less effective as treatment for solid tumours. Here the authors, utilising B7H3 as an antigen, consider how changes in B7H3 binders lead to functional changes of CAR-...

🚨 Avidity of clinical-stage aB7H3 scFv CAR-T's predicts function 🚨

The conclusions took us by surprise, in the opposite direction of canonically held knowledge about CD19- CARs in leukaemia

Check out our latest story in
@natureportfolio.nature.com
www.nature.com/articles/s41...

🌟 I’ve written a children’s book about vaccines- probably the greatest ever paediatric health innovation.

I struggled to find resources to explain this to my son that were accessible to him, so I wrote my own.
Everyone is welcome to our story time! 🔬

You can find the book here: amzn.eu/d/3QNB5Xh.

Engineering innate immune cells for cancer immunotherapy - Nature Biotechnology The unique attributes of innate immune cells position them as attractive candidates for cancer immunotherapy, with engineering strategies to enhance their antitumor potential, offering notable therape...

🚨🔬 Happy to share our review out in Nat Biotech

Great collab on Mϕ, γδT and NK cell translational success (and fails) with colleagues from Harvard&Zhejiang.

What can we learn from innate immune tx trials, how can we do better and what next for the field?

www.nature.com/articles/s41587-025-02629-5